Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Rinvoq (upadacitinib) and Xeljanz (tofacitinib) are both JAK inhibitors used to treat inflammatory conditions like rheumatoid arthritis and ulcerative colitis. However, they have some differences. Rinvoq is available as an extended-release tablet and an oral solution, while Xeljanz comes in immediate-release and extended-release tablets, as well as a liquid form. Rinvoq is typically taken once daily, whereas Xeljanz can be taken once or twice daily, depending on the formulation. Both medications are approved to treat additional inflammatory conditions; Rinvoq is approved for eczema and Crohn's disease, but Xeljanz is not. Common side effects of Rinvoq include acne and upper respiratory infections, while Xeljanz may cause diarrhea and headaches. Both medications can increase the risk of serious infections and blood clots. Rinvoq and Xeljanz both interact with many medications, including grapefruit juice. Both medications require careful monitoring and should not be used with live vaccines.
Rinvoq (upadacitinib)
Xeljanz (tofacitinib)
Rinvoq (upadacitinib)
Xeljanz (tofacitinib)
Summary of Rinvoq vs. Xeljanz
Summary for JAK inhibitor
Prescription only
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor. It's used to treat certain inflammatory conditions, such as rheumatoid arthritis (RA), ulcerative colitis (UC), and eczema (atopic dermatitis). But it's not a first-choice option and typically only prescribed when other treatments haven't worked well. Rinvoq (upadacitinib) is taken by mouth, usually once daily. It's available as an extended-release tablet (Rinvoq) and an oral solution (Rinvoq LQ), but the two formulations aren't interchangeable. Side effects include a higher risk of infections, acne, and nausea.
Summary for JAK inhibitor
Prescription only
Xeljanz (tofacitinib) is an oral medication that can treat different inflammatory problems. It can help adults with psoriatic arthritis, rheumatoid arthritis (RA), and ulcerative colitis, among other conditions. It's also helpful for children with a certain kind of arthritis. Xeljanz (tofacitinib) is a JAK inhibitor that lowers inflammation in the body. It comes as a tablet or liquid that's taken twice a day. There's also a longer-lasting once-daily tablet for adults. Xeljanz (tofacitinib) is a good option for people who've tried other medications first. But it can have side effects like headache, diarrhea, and a higher risk of infection. This medication is brand name only; there isn't a generic yet.
Indications of Rinvoq vs. Xeljanz
Indications for
Moderate-to-severe inflammatory conditions in which other treatments haven't worked:
•Moderate-to-severe polyarticular course juvenile idiopathic arthritis (pcJIA) in children 2 years and older - immediate-release tablets and liquid only
Pros and Cons of Rinvoq vs. Xeljanz
Pros and Const for JAK inhibitor
Pros
•Can treat many different inflammatory conditions
•Available as a tablet and a liquid
•The tablet only needs to be taken once a day
Cons
•Can raise risk for infections
•Not the best option for people with severe liver or kidney problems
•Not safe for use during pregnancy
Pros and Const for JAK inhibitor
Pros
•Liquid form available for the immediate-release version if you have trouble swallowing pills whole
•Extended-release, once-daily tablets available for adults
•Good option for people when other treatments haven't worked well